| Primary |
| Breast Cancer |
39.2% |
| Pain |
7.0% |
| Rhabdomyosarcoma |
6.1% |
| Gastric Cancer |
5.0% |
| Nausea |
4.7% |
| Non-small Cell Lung Cancer |
4.4% |
| Hepatic Neoplasm Malignant |
4.0% |
| Breast Cancer Metastatic |
3.8% |
| Hypertension |
3.3% |
| Product Used For Unknown Indication |
3.3% |
| Constipation |
3.2% |
| Prophylaxis |
2.9% |
| Chemotherapy |
2.4% |
| Breast Cancer Female |
2.2% |
| Sarcoma |
1.6% |
| Bladder Cancer |
1.6% |
| Insomnia |
1.6% |
| Vomiting |
1.4% |
| Analgesic Therapy |
1.2% |
| Cancer Pain |
1.2% |
|
| Neutropenia |
13.2% |
| Interstitial Lung Disease |
10.0% |
| Pneumonia |
7.3% |
| Vomiting |
5.9% |
| Sepsis |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Leukopenia |
5.0% |
| Cardiac Failure |
4.6% |
| Febrile Neutropenia |
4.6% |
| Progressive Multifocal Leukoencephalopathy |
4.6% |
| Pyrexia |
4.6% |
| General Physical Health Deterioration |
4.1% |
| Anaemia |
3.7% |
| Dyspnoea |
3.7% |
| Respiratory Failure |
3.7% |
| Pulmonary Embolism |
3.2% |
| Death |
2.7% |
| Nausea |
2.7% |
| Neutropenic Colitis |
2.7% |
| Pain |
2.7% |
|
| Secondary |
| Breast Cancer |
42.9% |
| Product Used For Unknown Indication |
14.6% |
| Gastric Cancer |
10.6% |
| Hodgkin's Disease |
3.8% |
| Drug Use For Unknown Indication |
3.8% |
| Breast Cancer Metastatic |
3.3% |
| Therapeutic Embolisation |
3.1% |
| Prophylaxis |
2.7% |
| Her-2 Positive Breast Cancer |
2.4% |
| Malignant Breast Neoplasm |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Hepatic Neoplasm Malignant |
1.3% |
| Chemotherapy |
1.2% |
| Diffuse Large B-cell Lymphoma |
1.2% |
| Pain |
1.1% |
| Rhabdomyosarcoma |
1.1% |
| Breast Cancer Female |
1.0% |
| Non-hodgkin's Lymphoma |
1.0% |
| Premedication |
0.9% |
| Neoplasm Malignant |
0.9% |
|
| Neutropenia |
8.2% |
| Drug Exposure During Pregnancy |
7.8% |
| Sepsis |
7.0% |
| Death |
6.1% |
| Febrile Neutropenia |
6.1% |
| Pulmonary Embolism |
5.3% |
| Pyrexia |
5.3% |
| Vomiting |
5.3% |
| Interstitial Lung Disease |
4.9% |
| Septic Shock |
4.9% |
| Diverticulitis Intestinal Haemorrhagic |
4.5% |
| Acute Myeloid Leukaemia |
4.1% |
| Alopecia |
4.1% |
| Malignant Neoplasm Progression |
4.1% |
| Pancreatitis |
4.1% |
| Pneumonia |
4.1% |
| Pancytopenia |
3.7% |
| Thrombocytopenia |
3.7% |
| Injection Site Phlebitis |
3.3% |
| Ischaemic Stroke |
3.3% |
|
| Concomitant |
| Breast Cancer |
33.7% |
| Prophylaxis Of Nausea And Vomiting |
13.1% |
| Metastases To Bone |
7.7% |
| Breast Cancer Metastatic |
7.3% |
| Product Used For Unknown Indication |
6.2% |
| Therapeutic Embolisation |
5.0% |
| Chemotherapy |
3.7% |
| Premedication |
3.5% |
| Hepatic Neoplasm Malignant |
2.5% |
| Neoplasm Malignant |
2.1% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Hypertension |
2.0% |
| Pain |
2.0% |
| Breast Cancer Female |
1.9% |
| Hepatocellular Carcinoma |
1.5% |
| Breast Cancer Recurrent |
1.3% |
| Prophylaxis |
1.3% |
| Mineral Supplementation |
1.1% |
| Nausea |
1.1% |
| Acute Lymphocytic Leukaemia |
0.9% |
|
| Hepatocellular Injury |
9.5% |
| Cytolytic Hepatitis |
7.1% |
| Injection Site Phlebitis |
7.1% |
| No Adverse Event |
7.1% |
| Flank Pain |
6.0% |
| Osteonecrosis |
6.0% |
| Injection Site Vasculitis |
4.8% |
| Metastases To Liver |
4.8% |
| Nausea |
4.8% |
| Urinary Retention |
4.8% |
| Vomiting |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Acute Myeloid Leukaemia |
3.6% |
| Cerebral Infarction |
3.6% |
| Diabetes Mellitus |
3.6% |
| Febrile Neutropenia |
3.6% |
| Hepatitis Fulminant |
3.6% |
| Hypertension |
3.6% |
| Infusion Related Reaction |
3.6% |
| Injection Site Erythema |
3.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
57.1% |
| Breast Cancer |
42.9% |
|
| Vomiting |
75.0% |
| Pyrexia |
25.0% |
|
